• Bafilomycin C1 in High-Content Assay Design

  2026-08-21

  Bafilomycin C1 is a vacuolar H+-ATPases inhibitor that can function as a mechanistic anchor in lysosomal and high-content phenotypic assays. This article explains how to distinguish V-ATPase-dependent acidification effects from nonspecific cellular injury, using deep-learning cardiotoxicity screening as a guide.

• Honokiol in CD8+ T-Cell Metabolism Research

  2026-08-20

  Use Honokiol to interrogate NF-κB signaling, oxidative stress, and inflammatory context alongside CD8+ T-cell metabolic assays. This workflow separates direct effects on the CD28–ARS2–PKM axis from broader pathway modulation, improving interpretation and reproducibility.

• Gastric Cancer Assembloids Model Tumor–Stroma Drug Response

  2026-08-20

  This 2025 study develops patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal cell subpopulations. The model shows that stromal composition alters gene expression and therapeutic sensitivity, providing a more physiologically relevant framework for resistance studies and personalized drug screening.

• 5X Protein Loading Buffer (Reducing) Guide

  2026-08-19

  5X Protein Loading Buffer (Reducing) standardizes denaturing and disulfide-bond reduction during protein sample preparation for conventional SDS-PAGE electrophoresis. It is appropriate when apparent protein molecular weight is being evaluated under reducing conditions, but not for native, non-reducing, or structure-preserving analyses.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-08-19

  The 1992 study by Jonas, Plant, and Henquin showed that several imidazoline α2-adrenoceptor antagonists enhance insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells. By combining 86Rb efflux, whole-cell patch clamp, and pharmacological antagonism experiments, the authors separated direct channel blockade from α2-adrenoceptor antagonism, providing a clearer framework for interpreting imidazoline effects on insulin secretion.

• Pazopanib Hydrochloride: Measuring Drug Response

  2026-08-18

  Pazopanib Hydrochloride and GW786034 are examined through a measurement-aware framework that separates growth arrest from cell killing. Learn how endpoint selection, timing, and model choice can improve interpretation in cancer research.

• Radiotherapy, PD-1/TIGIT Blockade, and Immune Memory

  2026-08-18

  This 2025 Cancer Letters study shows that radiotherapy combined with PD-1 and TIGIT blockade can generate both local tumor control and abscopal responses through activated, less-exhausted CD8+ T cells. Its use of immune profiling, cytokine analysis, rechallenge, and adoptive-transfer experiments links M1 macrophage activation with durable central-memory T-cell responses.

• Lysis Buffer for Reliable Mouse Genotyping

  2026-08-17

  A scientifically grounded guide to using lysis buffer as a rapid genotyping kit component for mouse tissue. It connects pre-analytical DNA quality and genotype assignment with the interpretation of sophisticated cancer-model studies, while clearly separating validated evidence from translational assumptions.

• ARCA EGFP mRNA for LNP Transfection Workflows

  2026-08-17

  ARCA EGFP mRNA provides a fast, direct fluorescence readout for comparing mRNA delivery, formulation toxicity, and mammalian cell gene expression. This workflow translates lessons from a GA/PPC-modified lipid nanoparticle study into practical assay controls without confusing reporter expression with therapeutic efficacy.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-16

  A 2025 study found that naturally occurring angiotensin peptide fragments can selectively enhance SARS-CoV-2 spike protein binding to AXL, ACE2, and neuropilin-1. Its peptide-truncation and tyrosine-modification experiments identify sequence features that may connect renin-angiotensin biology with viral receptor engagement, while also showing why binding assays should not be equated with infection outcomes.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-08-15

  Lee and colleagues used anthraquinone-based structural optimization to discover compound 8c, a potent allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with activity in biochemical, metabolic, allergic, and cancer-related models. The study combines medicinal chemistry, pharmacokinetic assessment, molecular docking, and disease-relevant experiments to support the lipoamide-binding site as a tractable design region, while leaving important questions about selectivity, long-term safety, and clinical translation unresolved.

• SLC2A5 Fructose Metabolism in PCNSL

  2026-08-14

  This Advanced Science study uses single-cell RNA and B-cell receptor profiling to show how glucose-poor, hypoxic conditions in primary central nervous system lymphoma reshape tumor and immune-cell metabolism. Functional testing identifies SLC2A5-dependent fructose uptake in lymphoma cells and tumor-supportive macrophages as a potential metabolic vulnerability linked to impaired T-cell function.

• Potassium Iodide in Thyroid Research Workflows

  2026-08-14

  Potassium Iodide offers a practical, water-compatible iodide source for thyroid uptake, hormone synthesis, and protection-model research. This guide also clarifies how KI can be used alongside, but should not be confused with, the MMP-2-responsive immunotherapy platform reported in breast cancer research.

• PNU 74654: Rethinking Wnt Pathway Translation

  2026-08-13

  A translational framework for using PNU 74654 to interrogate Wnt/β-catenin biology across cancer, stem cell, and progenitor-cell models without confusing pathway engagement with therapeutic validation.

• Talabostat mesylate: FAP, DPP4 & Assay Design

  2026-08-13

  Explore how Talabostat mesylate (PT-100) connects DPP4 and FAP inhibition with tumor microenvironment studies and better assay design. This article adds an epithelial-homeostasis perspective from NLRP10 research while clearly separating evidence, hypotheses, and practical limitations.

16391 records 1/1093 page Next 12345 下5页 Last page